RxDoctor Payments Data

Alejandra Uchio, MD

Ophthalmology · Montebello, CANPI 1144217191

Payments from drug & device makers

$3,872in general payments, 2019–2025

Across 166 payments — averaging $23.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$897
  • Sun Pharmaceutical Industries Inc.$628
  • NEW World Medical,inc.$500
  • Bausch & Lomb Americas Inc.$462
  • Oyster Point Pharma, Inc.$312
  • AbbVie$248
  • plus $825 from 10 others

What the payments were for

  • Consulting fees$50013%
  • Food & beverage$3,35487%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,872 in reported general payments places this provider in the 70th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$316,310
Medicare patients
826
Services billed
3,515

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cyclosporine1,497$825,568
RestasisCyclosporine1,056$738,553
XiidraLifitegrast225$292,411
LumiganBimatoprost285$116,142
MieboPerfluorohexyloctane/Pf76$55,880
Alphagan PBrimonidine Tartrate157$39,377
SimbrinzaBrinzolamide/Brimonidine Tart175$36,850
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol371$28,523
Brimonidine Tartrate314$28,395
CombiganBrimonidine Tartrate/Timolol136$26,879
Restasis MultidoseCyclosporine39$25,079
Prednisolone Acetate774$19,573
Latanoprost2,011$16,995
RhopressaNetarsudil Mesylate38$15,921
Brinzolamide96$14,550

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P, Combigan, Restasis Multidose$248$946,0301,673 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta$462$353,625312 claims
AlconSimbrinza$897$36,850175 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$32$8,86473 claims
Sun Pharmaceutical Industries Inc.Cequa$628$8,17815 claims
NovartisIlevro$229$4,28312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Montebello

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →